165 related articles for article (PubMed ID: 34536122)
1. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Sievers P; Stichel D; Sill M; Schrimpf D; Sturm D; Selt F; Ecker J; Kazdal D; Miele E; Kranendonk MEG; Tops BBJ; Kohlhof-Meinecke P; Beschorner R; Kramm CM; Hasselblatt M; Reifenberger G; Capper D; Wesseling P; Stenzinger A; Milde T; Korshunov A; Witt O; Pfister SM; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Dec; 142(6):1065-1069. PubMed ID: 34536122
[No Abstract] [Full Text] [Related]
2. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case.
Whiteway SL; Betts AM; O'Neil ER; Green AL; Gilani A; Orr BA; Mathis DA
J Pediatr Hematol Oncol; 2020 Nov; 42(8):e813-e818. PubMed ID: 31929384
[TBL] [Abstract][Full Text] [Related]
4. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
5. GOPC-ROS1 mosaicism in agminated Spitz naevi: report of two cases.
Goto K; Pissaloux D; Kauer F; Huriet V; Tirode F; de la Fouchardière A
Virchows Arch; 2021 Sep; 479(3):559-564. PubMed ID: 33733342
[TBL] [Abstract][Full Text] [Related]
6. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
[TBL] [Abstract][Full Text] [Related]
7. Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.
Karayan-Tapon L; Cortes U; Rivet P; Jermidi C; Vassal G; Wager M; Taillandier L
Eur J Cancer; 2014 Sep; 50(13):2364-6. PubMed ID: 24999209
[No Abstract] [Full Text] [Related]
8. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
[TBL] [Abstract][Full Text] [Related]
9. Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report.
Wang J; Luo S; Li Y; Zheng H
Medicine (Baltimore); 2021 Jan; 100(3):e24377. PubMed ID: 33546077
[TBL] [Abstract][Full Text] [Related]
10. Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor.
Kiehna EN; Arnush MR; Tamrazi B; Cotter JA; Hawes D; Robison NJ; Fong CY; Estrine DB; Han JH; Biegel JA
J Neurosurg Pediatr; 2017 Jul; 20(1):51-55. PubMed ID: 28387643
[TBL] [Abstract][Full Text] [Related]
11. Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer.
O'Neil SR; Weber GA; Deming DA; Burkard ME; Kenny PA; Richmond CS; Parsons BM
JCO Precis Oncol; 2023 Jul; 7():e2300174. PubMed ID: 37487149
[No Abstract] [Full Text] [Related]
12. GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.
Zeng L; Yang N; Zhang Y
J Thorac Oncol; 2018 Jul; 13(7):e114-e116. PubMed ID: 29935846
[No Abstract] [Full Text] [Related]
13. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
[TBL] [Abstract][Full Text] [Related]
14. ROS1 fusions in cancer: a review.
Uguen A; De Braekeleer M
Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
[TBL] [Abstract][Full Text] [Related]
15. [Infant-type hemispheric glioma with EEF1G-ROS1 fusion: report of a case].
Gao M; Wang LM; Piao YS; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):408-410. PubMed ID: 36973207
[TBL] [Abstract][Full Text] [Related]
16. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract][Full Text] [Related]
17. Novel
Deland L; Keane S; Bontell TO; Fagman H; Sjögren H; Lind AE; Carén H; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Genomics Proteomics; 2022; 19(6):711-726. PubMed ID: 36316040
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS
Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398
[TBL] [Abstract][Full Text] [Related]
19. Liver Mass in a Young Male With Ollier Disease.
Govalan R; Guindi M; Yang JD
Gastroenterology; 2021 Nov; 161(5):e4-e5. PubMed ID: 33812890
[No Abstract] [Full Text] [Related]
20. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]